This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Lindsay Musial, PharmD
Advertisement
Articles by Lindsay Musial, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes
2
Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk
3
DOJ Abandons Olmstead Defense as Texas v Kennedy Advances
4
MRI Shows Hypothalamic Atrophy in Narcolepsy Type 1, Sparing Subregion
5